KPV
| Category | Healing & Recovery |
| Goals | Gut Health · Immune Support · Skin & Hair |
| Evidence level | Preclinical (mostly cell/animal models) |
| Legal status | Research-only — not approved for human use |
| FDA status | Not FDA-approved; on PCAC 503A agenda Jul 23, 2026 (use evaluated: wound healing & inflammation) |
| Half-life | Not well established; short (small tripeptide) |
| Routes | Oral · Subcutaneous · Topical |
| CAS / MW / Sequence | 67727-97-3 · 342.4 g/mol · KPV (Lys-Pro-Val, 3 aa) |
| Last reviewed | 2026-06-07 |
In one line
A small anti-inflammatory tripeptide (the C-terminal fragment of α-MSH) studied mainly in cell and animal models for gut inflammation, immune modulation, and skin.
Evidence at a glance
KPV’s anti-inflammatory activity is reproducible in cell and rodent models (notably colitis), but there are no large human clinical trials for its popular uses. Treat human-use claims as extrapolation. See Evidence Grading Explained and the Disclaimer.
Key Takeaways
- A tripeptide (Lys-Pro-Val) corresponding to the C-terminal 11–13 residues of α-MSH.
- Retains α-MSH’s anti-inflammatory activity without the pigmentation (tanning) or appetite effects of the parent hormone.
- Acts both intracellularly (inhibiting NF-κB signaling) and via melanocortin receptors — strongest data in gut/colitis models.
- Unusually oral-active for a peptide; also explored topically for skin and subcutaneously.
- Not FDA-approved; sold as a research chemical. Appears in skin/healing blends like GLOW / KLOW.
What Is It
KPV is a synthetic tripeptide made of lysine, proline, and valine — the same three amino acids that form the C-terminal tail (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH). α-MSH is a potent natural anti-inflammatory peptide, and much of that activity is concentrated in this short tail. Because KPV lacks the receptor regions responsible for tanning and appetite effects, it is studied as a “clean” anti-inflammatory fragment. It is of particular interest because, unlike most peptides, it shows activity when given orally in colitis models.
Mechanism of Action
Mechanisms come mainly from cell and animal studies:
- NF-κB pathway inhibition (in-vitro) — KPV enters cells and inhibits IκB kinase, reducing NF-κB nuclear translocation and downstream pro-inflammatory gene expression.
- Cytokine reduction (cell/animal) — lowers TNF-α, IL-6, and related inflammatory mediators.
- Melanocortin receptor activity (in-vitro) — interacts with MC1R/MC3R, contributing to anti-inflammatory and possible antimicrobial effects.
- Gut transport (PepT1) (in-vitro) — taken up by intestinal/immune cells via the peptide transporter PepT1, supporting its activity in the gut lining.
- Antimicrobial activity (in-vitro) — α-MSH-derived peptides show direct activity against some bacteria and fungi.
Limitations
Most mechanistic data is in-vitro or rodent. Human pharmacology, bioavailability, and dosing are not well characterized.
Evidence by Outcome
| Outcome | Evidence | Notes |
|---|---|---|
| Intestinal inflammation / colitis | Preclinical | Reduced inflammation in mouse colitis (incl. oral dosing) |
| General anti-inflammatory effect | Preclinical | Consistent NF-κB/cytokine suppression in cell models |
| Skin inflammation / healing | Preclinical / Anecdotal | In blends (GLOW/KLOW); limited controlled data |
| Immune modulation | Preclinical | Reduced inflammatory immune-cell activation in models |
| Gut/“leaky gut” repair in humans | Anecdotal | Popular claim; no controlled human trials |
Reported Dosing
Not medical advice
Protocols as reported in community sources and non-clinical literature. There is no established human therapeutic dose. See Reconstitution & Dosing Math.
| Route | Dose (reported) | Frequency | Cycle |
|---|---|---|---|
| Oral (capsule) | ~250–500 µg/day | 1–2× daily | Variable (gut goals) |
| Subcutaneous | ~200–500 µg/day | 1× daily | ~4–8 weeks |
| Topical | In creams/blends | 1–2× daily | Variable (skin goals) |
Pharmacokinetics
As a very small tripeptide, KPV is expected to have a short half-life, though human PK is not well established. Its notable feature is oral activity — uptake via the intestinal peptide transporter (PepT1) is proposed to allow it to act locally in the gut, unusual for peptides that are normally digested. See Half-Life & Pharmacokinetics.
Side Effects & Risks
- Human safety data is limited; tolerability is inferred from small models, not chronic human use.
- Anecdotal reports: generally well tolerated; occasional injection-site irritation or mild GI changes — not systematically documented.
- Sourcing risk: as a research chemical, identity/purity vary — small peptides can be under-filled or mislabeled. See Sourcing and Red Flags & Scams.
- See Side Effects & Risk Management.
Cycling
Anecdotal protocols run KPV for 4–8 weeks for a specific inflammatory or gut goal, then reassess. No evidence-based cycling standard exists. See Cycling.
Stacks It Appears In
- GLOW / KLOW — skin/healing blends; KPV is the anti-inflammatory component
- Often paired with BPC-157 for gut-focused protocols
Comparisons
- vs BPC-157 — both are used for Gut Health; BPC-157 emphasizes tissue repair/angiogenesis, KPV emphasizes anti-inflammatory (NF-κB) signaling. They are commonly combined rather than chosen one-or-the-other.
- vs GHK-Cu — both appear in skin blends; GHK-Cu targets collagen/remodeling, KPV targets inflammation.
Sourcing & Quality
Sold as a lyophilized “research chemical.” Because it is a tiny tripeptide, accurate fill weight and identity matter and are not guaranteed. Verify before trusting a product: How to Read a CoA, HPLC vs Mass Spec, Third-Party Testing, Red Flags & Scams. Reconstitution and storage: Reconstitution & Dosing Math, Storage & Handling. No vendors are endorsed here.
Legal & Regulatory Status
(As of 2026-06-07.) Not FDA-approved for human use and sold as a research chemical. KPV-related bulk drug substances (KPV free base / acetate) are on the agenda of the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23, 2026, being considered for inclusion on the 503A Bulks List; the uses FDA evaluated are wound healing and inflammatory conditions (public docket FDA-2025-N-6895). Inclusion would only determine eligibility for traditional (503A) pharmacy compounding — it is not drug approval. Status varies by country and may be restricted in tested sport. See Regulatory & Legal Status.
FAQ
Is KPV FDA-approved? No. It is not approved for human use and is sold as a research chemical.
Where does KPV come from? It is the C-terminal three amino acids (Lys-Pro-Val) of α-MSH, retaining anti-inflammatory activity without tanning or appetite effects.
Can KPV be taken orally? Uniquely for a peptide, it shows oral activity in gut-inflammation models (via PepT1 uptake). Subcutaneous and topical routes are also reported.
Does KPV work in humans? The anti-inflammatory data is mostly cell/animal. Human use is largely extrapolation and anecdote.
What is it usually stacked with? Skin blends like GLOW / KLOW, and often BPC-157 for gut goals.
References
- Brzoska T. et al. (2008). “α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo.” Endocrine Reviews.
- Kannengiesser K. et al. (2008). “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflammatory Bowel Diseases.
- Dalmasso G. et al. (2008). “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology.
- Cutuli M. et al. (2000). “Antimicrobial effects of α-MSH peptides.” Journal of Leukocyte Biology.
- U.S. FDA (2026). “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee” — KPV (free base/acetate), uses evaluated: wound healing & inflammatory conditions; Docket FDA-2025-N-6895. fda.gov
← Healing & Recovery · Home Educational information only — not medical advice. See Disclaimer.